Active ingredient
- melphalan hydrochloride
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL 31750/0136 .
Melphalan 50 mg powder and solvent for solution for injection/infusion
Package leaflet: Information for the patient
Melphalan 50 mg powder and solvent for solution for injection/infusion
melphalan
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
What is in this leaflet
1. What Melphalan is and what it is used for
2. What you need to know before you are given Melphalan
3. How Melphalan will be given
4. Possible side effects
5. How to store Melphalan
6. Contents of the pack and other information
1. What Melphalan is and what it is used for
Melphalan contains a medicine called melphalan. This belongs to a group of medicines called cytotoxics (also called chemotherapy). Melphalan is used to treat cancer. It works by reducing the number of abnormal cells your body makes.
Melphalan is used for:
You must talk to a doctor if you do not feel better or if you feel worse.
2. What you need to know before you are given Melphalan
You should NOT be given Melphalan if any of following apply to you. Tell your doctor if:
Warnings and precautions
Before treatment with Melphalan, tell your doctor if any of the following apply to you:
Other medicines and Melphalan
Tell your doctor or nurse if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
In particular, tell your doctor or nurse if you are taking any of the following
Pregnancy, breastfeeding and fertility
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before this medicine is given.
Pregnancy
Treatment with Melphalan is not recommended during pregnancy because it may cause permanent damage to a foetus. If you are already pregnant, it is important to talk to your doctor before being given Melphalan. Your doctor will consider the risks and benefits to you and your baby of treatment with Melphalan.
Reliable contraceptive precautions must be taken to avoid pregnancy whilst you or your partner are having this injection/infusion.
Breastfeeding
It is unknown whether Melphalan is excreted in human breast milk. Do not breastfeed while being given Melphalan.
Fertility
Melphalan can affect ovaries or sperm, which may cause infertility (inability to have a baby). In women, menstruation can stop (amenorrhoea) and in men, a complete lack of sperm can be observed (azoospermia) as a result of Melphalan treatment. Therefore men are advised to have a consultation on sperm preservation before treatment.
Male and female contraception
It is recommended that men who are receiving Melphalan do not father a child during treatment and up to 3 months afterwards. Talk to your doctor if you would like to use effective and reliable contraceptives.
Driving and using machines
Effects on the ability to drive and operate machinery in patients taking this medicine have not been studied. It is not expected that this medicine will affect the ability to drive or operate machines.
Melphalan contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium-free’.
Melphalan contains ethanol (alcohol)
This medicine contains 5% ethanol (alcohol), equivalent to 10 ml beer or 2.4 ml wine per dose. Harmful for those suffering from alcoholism.
To be taken into account in pregnant or breastfeeding women, children and high-risk groups such as patients with liver disease, or epilepsy.
Melphalan contains propylene glycol
May cause alcohol-like symptoms.
3. How Melphalan will be given
Melphalan will only be given to you by doctors or nurses experienced in giving chemotherapy.
Method of administration
Melphalan can be given
How much Melphalan is given
Your doctor will decide how much Melphalan you will be given. The amount of Melphalan depends on
When you are given Melphalan, your doctor will take regular blood tests. This is to check the number of cells in your blood. Your doctor may change your dose as a result of these tests.
Risk of blood clots(thromboembolic events)
Your doctor will decide if you should receive a preventive treatment for blood clots in the veins. This applies during the first 5 months of treatment, or if you have an increased risk for developing a blood clot in the veins.
Use in children
Melphalan is only rarely used in children. Dosing guidelines for children are not available.
Use in elderly
There are no specific dosage adjustments for the elderly.
Use in patients with impaired renal function
If you have a kidney problem, your doctor will usually give you a lower dose than other adults.
If you are given more Melphalan than you should
Your doctor will give you Melphalan so it is unlikely that you will receive too much. If you think you have been given too much or have missed a dose, tell your doctor or nurse.
If you forget to use Melphalan
Your doctor will give you Melphalan so it is unlikely that you will miss a dose of this medicine. If you think you have missed a dose, skip that dose and you will be given next dose at the next prescribed time. Do not use a double dose to make up for a forgotten dose.
If you stop using Melphalan
If you feel you should stop using this medicine, consult your doctor first.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
If you get any of the following, talk to your specialist doctor or go to hospital straight away:
Tell your doctor immediately if you have symptoms of blood clots in the veins, especially in the legs. Symptoms include swelling, pain and reddening of the leg. Blood clots can travel through the blood vessels to the lungs, causing pain on the chest and difficulties in breathing.
Other side effects include:
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Rare side effects (may affect up to 1 in 1,000 people)
Not known (frequency cannot be estimated from the available data)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Melphalan
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and the outer packaging after EXP. The expiry date refers to the last day of that month.
Do not store above 30°C. Do not refrigerate. Keep the vial in the outer carton in order to protect from light.
Your Melphalan will be prepared for use by a healthcare professional. Once prepared it should be used immediately and must not be stored or refrigerated.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Melphalan contains
What Melphalan looks like and contents of the pack
Each pack Melphalan contains one vial of Melphalan powder and one vial of solvent. The powder vial contains 50 mg of the active substance mephalan in a powder format and the solvent vial contains 10 ml of solvent in which to reconstitute (dissolve) the powder. The powder is a white to off-white freeze-dried powder or cake and the solvent is a clear colourless liquid/solution. After reconstitution with 10 ml of the solvent, the resultant solution contains 5 mg/ml melphalan.
Marketing Authorisation Holder
Manufacturer
This medicinal product is authorised in the Member States of the EEA under the following names:
Germany: Melphalan SUN
France: Melphalan SUN
Italy: Melfalan SUN
Netherlands: Melfalan hydrochloride SUN
Sweden: Melfalan SUN
United Kingdom: Melphalan
This leaflet was last revised in July 2018
V001
5th Floor, Hyde Park, Hayes, 3, 11 Millington Road, Hayes, UB3 4AZ, UK
+44 (0) 208 848 8688
+44 (0) 208 848 5052